Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.

AIMT has been the topic of several other research reports. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a research note on Saturday, October 21st. Wedbush reissued an outperform rating and set a $70.00 target price on shares of Aimmune Therapeutics in a research note on Friday, December 1st. Zacks Investment Research lowered Aimmune Therapeutics from a hold rating to a sell rating in a research note on Monday, January 8th. BidaskClub lowered Aimmune Therapeutics from a buy rating to a hold rating in a research report on Thursday, January 4th. Finally, Roth Capital began coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They issued a buy rating and a $60.00 price target on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $55.43.

Aimmune Therapeutics (NASDAQ AIMT) traded up $0.78 on Thursday, reaching $39.43. The company had a trading volume of 370,464 shares, compared to its average volume of 364,163. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. analysts forecast that Aimmune Therapeutics will post -2.51 earnings per share for the current year.

In other Aimmune Therapeutics news, insider Daniel C. Md Adelman sold 3,283 shares of the stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $40.00, for a total value of $131,320.00. Following the sale, the insider now owns 3,283 shares of the company’s stock, valued at approximately $131,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Susan E. Barrowcliffe sold 75,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $37.14, for a total value of $2,785,500.00. The disclosure for this sale can be found here. Insiders sold a total of 137,946 shares of company stock worth $4,991,189 in the last ninety days. 24.56% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Daiwa SB Investments Ltd. increased its holdings in shares of Aimmune Therapeutics by 44.5% in the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,245 shares during the last quarter. Franklin Street Advisors Inc. NC increased its holdings in shares of Aimmune Therapeutics by 43.8% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 16,420 shares of the biotechnology company’s stock valued at $621,000 after acquiring an additional 5,000 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Aimmune Therapeutics by 10.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after acquiring an additional 101,855 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Aimmune Therapeutics by 4.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 110,580 shares of the biotechnology company’s stock valued at $2,742,000 after acquiring an additional 4,891 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Aimmune Therapeutics by 3.4% in the 3rd quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock valued at $1,519,000 after acquiring an additional 2,025 shares during the last quarter. Institutional investors and hedge funds own 73.34% of the company’s stock.

WARNING: “Aimmune Therapeutics (AIMT) PT Set at $45.00 by Credit Suisse Group” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/01/14/aimmune-therapeutics-aimt-pt-set-at-45-00-by-credit-suisse-group.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.